SCHEMBL6905755

SCHEMBL6905755

Cc1cc(Cl)cc(N=C2C(=O)N(c3ccccc3)c3ccccc32)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GALR3 O60755 11/20 0.58
HTR4 Q13639 1/20 0.58
MAPT P10636 5/20 0.49
KMT2A Q03164 4/20 0.49
MEN1 O00255 1/20 0.49
NPSR1 Q6W5P4 2/20 0.47
TTR P02766 2/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
ALDH1A1 P00352 2/20 0.44
CES2 O00748 1/20 0.44
BCHE P06276 1/20 0.44
GAA P10253 1/20 0.44
CES1 P23141 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
DRD5 P21918 1/20 0.43
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8171379 1.00 GALR3 (0.58) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL916941 0.91 GALR3 (0.64) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL915682 0.91 GALR3 (0.60) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL916940 0.91 GALR3 (0.64) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL915680 0.91 GALR3 (0.60) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL8084764 0.87 GALR3 (0.44) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL12903538 0.87 GALR3 (0.44) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL916817 0.84 GALR3 (0.68) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL916818 0.84 GALR3 (0.68) GALR3HTR4MAPTKMT2AMEN1
SCHEMBL917358 0.84 GALR3 (0.72) GALR3HTR4MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198313-B2 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods H. LUNDBECK A/S (DK) 2012-06-12 US disclosed
US-20110178125-A1 USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS KONKEL MICHAEL 2011-07-21 US disclosed
US-7868034-B2 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods H. LUNDBECK A/S (DK) 2011-01-11 US disclosed
US-20100179187-A1 INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2010-07-15 US disclosed
US-20090318504-A1 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods BLACKBURN THOMAS P 2009-12-24 US disclosed
US-20090176840-A1 USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS KONKEL MICHAEL 2009-07-09 US disclosed
US-20080039496-A1 Method of Modulating Neurite Outgrowth by the use of a Galanin-3 Receptor Antagonist HELICON THERAPEUTICS, INC. 2008-02-14 US disclosed
US-7220775-B2 Compound useful for the treatment of neuropathic pain H. LUNDBECK A/S (DK) 2007-05-22 US disclosed
US-20070054910-A1 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods KONKEL MICHAEL 2007-03-08 US disclosed
US-20040110821-A1 administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative H. LUNDBECK A/S (DK) 2004-06-10 US disclosed
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318504-A1 Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods GALR3, GALR2, GALR1 GALR3 1/4885HTR4 30/4885MAPT 3040/4885
US-20080039496-A1 Method of Modulating Neurite Outgrowth by the use of a Galanin-3 Receptor Antagonist GALR3, GALR2, GAP43 GALR3 1/4885HTR4 426/4885MAPT 1502/4885
US-20100179187-A1 INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT CHAT, AANAT, TPH2 GALR3 450/4885HTR4 12/4885MAPT 100/4885
US-20110178125-A1 USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS GALR3, GALR1, GALR2 GALR3 1/4885HTR4 30/4885MAPT 2912/4885
US-20040110821-A1 administering to the subject suffering from affective disorder a 3-IMINO-1,3-DIHYDRO-2H-INDOL-2-ONE derivative GALR3, GALR2, GALR1 GALR3 1/4885HTR4 17/4885MAPT 1723/4885
US-20040092570-A1 GAL3 antagonists for the treatment of neuropathic pain GALR3, GALR2, GALR1 GALR3 1/4885HTR4 214/4885MAPT 3177/4885
US-20070054910-A1 Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods GALR3, GALR1, GALR2 GALR3 1/4885HTR4 30/4885MAPT 2912/4885
US-20090176840-A1 USE OF GALR3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DEPRESSION AND/OR ANXIETY AND COMPOUNDS USEFUL IN SUCH METHODS GALR3, GALR1, GALR2 GALR3 1/4885HTR4 31/4885MAPT 2848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.